toxylact: a02aa02 magnesium oxide

The first professional lActological database in the word

Active substance and ATC code

Magnesium oxide (MgO), also known as magnesia, is an inorganic magnesium salt classified as an antacid in the ATC group A02A (magnesium compounds) with the code A02AA02. It is widely used in clinical practice as an antacid and osmotic laxative, and as a source of elemental magnesium in nutritional supplementation.


Pharmacotherapeutic group and indications

Magnesium oxide belongs to the pharmacotherapeutic group of magnesium‑containing antacids and oral magnesium supplements. It is indicated for short‑term relief of acid indigestion and dyspepsia, as a laxative (including bowel preparation), and for treatment or prevention of magnesium deficiency when dietary intake is insufficient.


Mechanism of action

As an antacid, magnesium oxide reacts with gastric hydrochloric acid, forming magnesium chloride and water, thereby neutralising gastric acidity and increasing intragastric pH. As an osmotic laxative, non‑absorbed magnesium ions retain water in the intestinal lumen, stimulate cholecystokinin release and enhance peristalsis, which accelerates colonic transit.


Pharmacokinetics in adults

Oral bioavailability of magnesium from magnesium oxide is low; a substantial fraction of the dose remains in the gastrointestinal lumen and is excreted in the faeces. Systemically absorbed magnesium is distributed mainly to bone and soft tissues, with excess eliminated via the kidneys, so patients with normal renal function efficiently regulate serum magnesium concentrations.


Usual dosage and administration

In adults, typical antacid doses are around 400 mg magnesium oxide orally once daily, whereas higher single doses (for example, about 3.5 g, often combined with stimulant laxatives) are used for bowel preparation. For nutritional supplementation, daily oral doses up to about 800 mg magnesium oxide are used, corresponding to usual supplemental intakes of approximately 200–400 mg elemental magnesium per day.


Contraindications and precautions

Magnesium oxide is contraindicated in patients with severe renal failure or clinically significant renal impairment due to the risk of magnesium accumulation and hypermagnesaemia. It should be used with caution in bowel obstruction and in patients receiving interacting medicines such as tetracyclines or bisphosphonates, where administration times should be separated by at least two hours to avoid reduced drug absorption.


Adverse effects and toxicity in the mother

At therapeutic doses, adverse reactions are usually mild and gastrointestinal, including abdominal cramps, diarrhoea, nausea, vomiting, and upset stomach. Excessive or prolonged dosing, especially in the presence of renal dysfunction, may lead to hypermagnesaemia, manifesting with flushing, hypotension, lethargy, diminished deep tendon reflexes, and, in severe cases, cardiac conduction disturbances.


Transfer into breast milk

Magnesium is a normal constituent of human milk with mean concentrations around 31 mg/L (range 15–64 mg/L), and these levels are not significantly altered by maternal oral magnesium intake. Because oral magnesium salts, including magnesium oxide, have low gastrointestinal absorption and any absorbed fraction is tightly homeostatically regulated, only minimal additional magnesium passes into breast milk.


Effects in breastfed infants

In term, healthy breastfed infants, the negligible increase in milk magnesium associated with maternal oral magnesium oxide is not expected to produce clinically relevant changes in infant serum magnesium or adverse effects. Theoretical concerns relate mostly to premature or very young neonates, whose increased intestinal permeability can result in higher magnesium absorption; in such cases careful clinical follow‑up is advisable if the mother uses magnesium chronically or at high doses.


Toxicological risk assessment during breastfeeding

Available clinical and pharmacokinetic data indicate that magnesium oxide is compatible with breastfeeding and is considered a very low–risk option for nursing mothers. Authoritative lactation‑oriented sources state that ingested magnesium does not concentrate in breast milk and that standard oral doses of magnesium salts are generally safe in lactating women, with no need to interrupt breastfeeding or discard milk.

When magnesium oxide is used at recommended antacid, laxative, or supplemental doses in mothers with normal renal function, toxicological risk to the breastfed infant is negligible, and breastfeeding can be continued without timing restrictions. Chronic high‑dose use or use in women with renal impairment may increase the maternal risk of hypermagnesaemia and, theoretically, could expose the infant to slightly higher magnesium levels, so such cases warrant individualised assessment and monitoring rather than routine contraindication of breastfeeding.


Clinical recommendations for lactating women

For healthy lactating women requiring short‑term treatment of dyspepsia or constipation, magnesium oxide is an appropriate first‑line antacid or osmotic laxative from a lactation safety perspective. The lowest effective dose and shortest effective duration should be used, and chronic or excessive self‑medication should be avoided, particularly in mothers of premature infants or in those with impaired renal function.

Healthcare professionals should counsel breastfeeding mothers on possible maternal gastrointestinal side effects (such as diarrhoea) and advise them to seek medical evaluation if symptoms of hypermagnesaemia or persistent digestive complaints occur. In most routine scenarios, maternal therapy with magnesium oxide does not require any change in breastfeeding practice, and the well‑established benefits of breastfeeding clearly outweigh any minimal theoretical toxicological risk.


Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.